ABSTRACT
OBJETIVO: Determinar en la población adulta las tasas de prevalencia brutas y ajustadas por edad y sexo de hipertrigliceridemia (HTG) y valorar su asociación con factores de riesgo cardiovascular, enfermedad renal crónica y enfermedades cardiovasculares y cardiometabólicas. MÉTODOS: Estudio observacional transversal realizado en Atención Primaria, con 6.588 sujetos de estudio adultos, seleccionados aleatoriamente con base poblacional. Los pacientes tenían HTG si la concentración de triglicéridos era≥150mg/dL (≥1,7mmol/L) o estaban en tratamiento hipolipidemiante para reducir los triglicéridos. Se valoraron las asociaciones mediante análisis univariado y multivariante, y se determinaron las prevalencias brutas y ajustadas por edad y sexo. RESULTADOS: Las medias aritméticas y geométricas de las concentraciones de triglicéridos fueron respectivamente 120,5 y 104,2mg/dL en la población global, 135,7 y 116,0mg/dL en hombres, y 108,6 y 95,7mg/dL en mujeres. Las prevalencias brutas de HTG fueron 29,6% en población global, 36,9% en hombres y 23,8% en mujeres. Las prevalencias ajustadas por edad y sexo de HTG fueron 27,0% en población global, 34,6% en hombres y 21,4% en mujeres. Las variables independientes que más se asociaban con la HTG fueron hipercolesterolemia (OR: 4,6), c-HDL bajo (OR: 4,1), esteatosis hepática (OR: 2,8), diabetes (OR: 2,0) y obesidad (OR: 1,9). CONCLUSIONES: Las medias de triglicéridos y las prevalencias de HTG se encuentran intermedias entre las de otros estudios nacionales e internacionales. La quinta parte de la población adulta femenina y más de un tercio de la masculina presentaba HTG. Los factores independientes asociados con HTG fueron hipercolesterolemia y c-HDL bajo, y las variables cardiometabólicas diabetes, esteatosis hepática y obesidad
AIM: To determine in the adult population the crude and the sex- and age-adjusted prevalence rates of hypertriglyceridaemia (HTG) and to assess its association with cardiovascular risk factors, chronic kidney disease, cardiovascular and cardiometabolic diseases. METHODS: Cross-sectional observational study conducted in Primary Care, with 6,588 adult study subjects, randomly selected on base-population. Patients had HTG if the triglyceride level was≥150mg/dL (≥1.7mmol/L), or were on lipid-lowering therapy to lower triglyceride. Associations were assessed by univariate and multivariate analysis, and crude and sex- and age-adjusted prevalence rates were determined. RESULTS: The arithmetic and geometric means of triglyceride levels were respectively 120.5 and 104.2mg/dL in global population, 135.7 and 116.0mg/dL in men, and 108.6 and 95.7mg/dL in women. The crude HTG prevalence rates were 29.6% in global population, 36.9% in men and 23.8% in women. The sex- and age-adjusted HTG prevalence rates were 27.0% in global population, 34.6% in men and 21.4% in women. The independent variables that were most associated with HTG were hypercholesterolemia (OR: 4.6), low HDL-C (OR: 4.1), hepatic steatosis (OR: 2.8), diabetes (OR: 2.0), and obesity (OR: 1.9). CONCLUSIONS: The means of triglyceride levels and HTG prevalence rates are intermediate between those of other national and international studies. A fifth of the female adult population and more than a third of the male population had HTG. The independent factors associated with HTG were hypercholesterolemia and low HDL-C, and the cardiometabolic variables diabetes, hepatic steatosis and obesity
Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Hypertriglyceridemia/epidemiology , Cardiovascular Diseases/complications , Primary Health Care , Cholesterol, LDL , Dyslipidemias , Risk Factors , Cross-Sectional Studies , Triglycerides/analysis , Fatty Liver/complications , Obesity/complications , Diabetes ComplicationsABSTRACT
AIM: To determine in the adult population the crude and the sex- and age-adjusted prevalence rates of hypertriglyceridaemia (HTG) and to assess its association with cardiovascular risk factors, chronic kidney disease, cardiovascular and cardiometabolic diseases. METHODS: Cross-sectional observational study conducted in Primary Care, with 6,588 adult study subjects, randomly selected on base-population. Patients had HTG if the triglyceride level was≥150mg/dL (≥1.7mmol/L), or were on lipid-lowering therapy to lower triglyceride. Associations were assessed by univariate and multivariate analysis, and crude and sex- and age-adjusted prevalence rates were determined. RESULTS: The arithmetic and geometric means of triglyceride levels were respectively 120.5 and 104.2mg/dL in global population, 135.7 and 116.0mg/dL in men, and 108.6 and 95.7mg/dL in women. The crude HTG prevalence rates were 29.6% in global population, 36.9% in men and 23.8% in women. The sex- and age-adjusted HTG prevalence rates were 27.0% in global population, 34.6% in men and 21.4% in women. The independent variables that were most associated with HTG were hypercholesterolemia (OR: 4.6), low HDL-C (OR: 4.1), hepatic steatosis (OR: 2.8), diabetes (OR: 2.0), and obesity (OR: 1.9). CONCLUSIONS: The means of triglyceride levels and HTG prevalence rates are intermediate between those of other national and international studies. A fifth of the female adult population and more than a third of the male population had HTG. The independent factors associated with HTG were hypercholesterolemia and low HDL-C, and the cardiometabolic variables diabetes, hepatic steatosis and obesity.
Subject(s)
Hypertriglyceridemia/epidemiology , Triglycerides/blood , Adult , Age Distribution , Analysis of Variance , Arteriosclerosis/prevention & control , Cross-Sectional Studies , Diabetes Mellitus/epidemiology , Fatty Liver/epidemiology , Female , Humans , Hypercholesterolemia/epidemiology , Hypertriglyceridemia/blood , Male , Metabolic Diseases , Obesity/epidemiology , Prevalence , Renal Insufficiency, Chronic , Sex DistributionABSTRACT
BACKGROUND: The most common cystic fibrosis (CF)-causing mutation is deltaF508 (F508del), which is present in 28% of CF Spanish patients. While the literature based on real-life studies on CF patients homozygous F508del treated with lumacaftor/ivacaftor is limited, it demonstrates the need for better strategies to prevent related adverse events (AEs) as well as the development of newer drugs. METHODS: We conducted a multicenter, retrospective, observational study to describe the effects of lumacaftor/ivacaftor treatment in real-life in Spain. 20 CF patients were included, all aged 6 and upwards and presented with ppFEV1<40%, chosen from CF units country-wide. For the purposes of the study, they were treated with lumacaftor/ivacaftor 200/125mg two tablets twice a day on a compassionate use programme throughout 2016. The primary endpoint was measured in all of the sample patients. Data were analysed from ppFEV1 at baseline and was measured every 6 months. RESULTS: The mean age was 26.65 (range of 10-45), while the mean ppFEV1 before the treatment was 32.4% and mean BMI was 19.9kg/m2. We analysed the changes in ppFEV1 and BMI from baseline during the treatment with lumacaftor/ivacaftor, but no differences were found. However, a moderate association between days of intravenous antibiotic needed and the use of lumacaftor/ivacaftor (p=0.001) was established. Indeed, under the lumacaftor/ivacaftor, patients required 5.8 days of intravenous antibiotic treatment compared to 14.9 days prior to study. Also, severe pulmonary exacerbations requiring hospitalisation were statistically fewer under lumacaftor/ivacaftor treatment (p=0.003). Finally, 75% of the sample presented with AEs, which led 35% of the subjects to discontinue the treatment. CONCLUSIONS: While treatment with lumacaftor/ivacaftor resulted in an improvement in the number of pulmonary severe exacerbations, no improvement in ppFEV1 or BMI was found.
Subject(s)
Aminophenols/administration & dosage , Aminopyridines/administration & dosage , Benzodioxoles/administration & dosage , Chloride Channel Agonists/administration & dosage , Compassionate Use Trials , Cystic Fibrosis/drug therapy , Quinolones/administration & dosage , Adolescent , Adult , Child , Drug Combinations , Female , Humans , Male , Middle Aged , Retrospective Studies , Spain , Young AdultABSTRACT
Background: The most common cystic fibrosis (CF)-causing mutation is deltaF508 (F508del), which is present in 28% of CF Spanish patients. While the literature based on real-life studies on CF patients homozygous F508del treated with lumacaftor/ivacaftor is limited, it demonstrates the need for better strategies to prevent related adverse events (AEs) as well as the development of newer drugs. Methods: We conducted a multicenter, retrospective, observational study to describe the effects of lumacaftor/ivacaftor treatment in real-life in Spain. 20 CF patients were included, all aged 6 and upwards and presented with ppFEV1 < 40%, chosen from CF units country-wide. For the purposes of the study, they were treated with lumacaftor/ivacaftor 200/125 mg two tablets twice a day on a compassionate use programme throughout 2016. The primary endpoint was measured in all of the sample patients. Data were analysed from ppFEV1 at baseline and was measured every 6 months. Results: The mean age was 26.65 (range of 10-45), while the mean ppFEV1 before the treatment was 32.4% and mean BMI was 19.9 kg/m2. We analysed the changes in ppFEV1 and BMI from baseline during the treatment with lumacaftor/ivacaftor, but no differences were found. However, a moderate association between days of intravenous antibiotic needed and the use of lumacaftor/ivacaftor (p = 0.001) was established. Indeed, under the lumacaftor/ivacaftor, patients required 5.8 days of intravenous antibiotic treatment compared to 14.9 days prior to study. Also, severe pulmonary exacerbations requiring hospitalisation were statistically fewer under lumacaftor/ivacaftor treatment (p = 0.003). Finally, 75% of the sample presented with AEs, which led 35% of the subjects to discontinue the treatment. Conclusions: While treatment with lumacaftor/ivacaftor resulted in an improvement in the number of pulmonary severe exacerbations, no improvement in ppFEV1 or BMI was found
Introducción: La mutación causante de fibrosis quística (FQ) más frecuente es la deltaF508 (F508del), presente en el 28% de los pacientes españoles con FQ. Aunque la literatura sobre estudios en vida real en pacientes de FQ homocigotos para F508del tratados con lumacaftor/ivacaftor es escasa, pone de manifiesto la necesidad de contar con mejores estrategias para prevenir los efectos adversos (EA) relacionados con el tratamiento, así como del desarrollo de nuevos fármacos. Métodos: Se realizó un estudio observacional, retrospectivo multicéntrico para describir los efectos del tratamiento con lumacaftor/ivacaftor en vida real en España. Se incluyeron 20 pacientes con FQ, edad superior a los 6 años y ppFEV1 < 40%, procedentes de unidades de FQ de todo el país. Para los fines del estudio, fueron tratados con 2 comprimidos de lumacaftor/ivacaftor 200/125 mg/2 veces al día como parte de un programa de uso compasivo a lo largo de 2016. El criterio de valoración primario se midió en las muestras de todos los pacientes. Los datos de ppFEV1 se analizaron al inicio y cada 6 meses. Resultados: La mediana de edad fue de 26,65 (rango: 10-45), mientras que la mediana de ppFEV1 antes del tratamiento fue del 32,4% y la mediana del IMC 19,9 kg/m2. No se encontraron diferencias al analizar los cambios de ppVEF1 e IMC desde el inicio y durante el tratamiento con lumacaftor/ivacaftor. Sin embargo, se estableció una asociación moderada entre los días requeridos de antibiótico intravenoso y el uso de lumacaftor/ivacaftor (p = 0,001). De hecho, con lumacaftor/ivacaftor, los pacientes requirieron 5,8 días de tratamiento intravenoso con antibiótico, comparado con los 14,9 días previos al estudio. Además, el número de exacerbaciones pulmonares graves que requirieron hospitalización fue estadísticamente menor con lumacaftor/ivacaftor (p = 0,003). Por último, el 75% de la muestra presentó EA, lo cual supuso la discontinuación del tratamiento en un 35% de los casos. Conclusión: El tratamiento con lumacaftor/ivacaftor mejoró el número de exacerbaciones pulmonares severas, pero no supuso mejora ni en el ppFEV1 ni el IMC
Subject(s)
Humans , Male , Female , Child , Adolescent , Young Adult , Adult , Middle Aged , Cystic Fibrosis/drug therapy , Aminophenols/administration & dosage , Aminopyridines/administration & dosage , Drug Combinations , Treatment Outcome , Retrospective Studies , Observational StudyABSTRACT
Se realizó un estudio descriptivo y transversal de 50 pacientes atendidas en el servicio de legrados del Hospital General Docente "Alberto Fernández Montes de Oca", del municipio San Luis, en el período comprendido desde abril hasta mayo de 1998, con el fin de determinar las ventajas del ketalar como anestesia general endovenosa, a través de la premedicación con difenhidramina y sin ella. Se determinó la aparición de complicaciones en cada uno de los grupos, así como también el costo de los medicamentos, donde se comprobó que éstos se reducen notablemente con la premedicación, lo que significa un ahorro para la unidad y para el Sistema Nacional de Salud(AU)
A descriptive and cross-sectional study of 50 patients cared at the service of curettages of "Alberto Fernández Montes de Oca" General Teaching Hospital, of San Luis municipality, was conducted in the period comprised from April to May of 1998 so as to determine the advantages of ketalar as a general endovenous anesthesia, through the premedication with diphenhydramine and without it. The appearance of complications in each of the groups was determined, as well as the medicines cost and it was checked that the costo can be remarkably reduced with the premedication which means a saving for the unit and for the National Health System(AU)
Subject(s)
Humans , Premedication/adverse effects , Curettage/methods , Diphenhydramine/therapeutic use , Anesthesia, Intravenous/adverse effects , Epidemiology, Descriptive , Cross-Sectional StudiesABSTRACT
Se realizó un estudio descriptivo y transversal de 50 pacientes atendidas en el servicio de legrados del Hospital General Docente "Alberto Fernández Montes de Oca", del municipio San Luis, en el período comprendido desde abril hasta mayo de 1998, con el fin de determinar las ventajas del ketalar como anestesia general endovenosa, a través de la premedicación con difenhidramina y sin ella. Se determinó la aparición de complicaciones en cada uno de los grupos, así como también el costo de los medicamentos, donde se comprobó que éstos se reducen notablemente con la premedicación, lo que significa un ahorro para la unidad y para el Sistema Nacional de Salud (AU)
Subject(s)
Curettage , Anesthesia, Intravenous/adverse effects , Premedication , Diphenhydramine/therapeutic use , Cross-Sectional StudiesABSTRACT
Se realizó un estudio analítico, longitudinal y prospectivo acerca de la analgesia acupuntural y los bloqueos terapéuticos empleados como procedimiento en 200 pacientes con lumbociatalgia, atendidos en la clínica para el tratamiento del dolor del Hospital General Docente "Alberto Fernández Montes de Oca" de San Luis, provincia de Santiago de Cuba, durante el período comprendido desde julio de 1996 hasta marzo de 1997, con el objetivo de precisar la respuesta al tratamiento, comparar su efectividad y mostrar la labor de Enfermería en la aplicación de ambas técnicas. Se encontró que el tratamiento acupuntural del dolor lumbociático produjo analgesia en todos los pacientes tratados con este método, que además de ser inocuo, resultó de muy bajo costo y arrojó una diferencia de $ 8 513 en comparación con la técnica tradicional(AU)
An analytical, longitudinal and prospective study about acupuncture analgesia and therapeutic blocks used a procedure in 200 patients with lumbosciatica attended at the clinic for the treatment of pain of the "Alberto Fernández Montes de Oca" General Teaching Hospital, in San Luis, province of Santiago de Cuba, from July, l996, to March, l997, was conducted aimed at determining the response to treatment, comparing its effectiveness and showing the work carried out by the nurses in the application of both techniques. It was found that the acupuncture treatment of lumbosciatica produced release in all the patients treated by this method, that besides being innocuos was very cheap. There was a difference of $8 513 compared with the traditional technique(AU)
Subject(s)
Humans , Sciatica/therapy , Acupuncture Analgesia/methods , Acupuncture Therapy/nursing , Low Back Pain/therapy , Nerve Block/nursing , Prospective Studies , Longitudinal StudiesABSTRACT
Se realizó un estudio analítico, longitudinal y prospectivo acerca de la analgesia acupuntural y los bloqueos terapéuticos empleados como procedimiento en 200 pacientes con lumbociatalgia, atendidos en la clínica para el tratamiento del dolor del Hospital General Docente "Alberto Fernández Montes de Oca" de San Luis, provincia de Santiago de Cuba, durante el período comprendido desde julio de 1996 hasta marzo de 1997, con el objetivo de precisar la respuesta al tratamiento, comparar su efectividad y mostrar la labor de Enfermería en la aplicación de ambas técnicas. Se encontró que el tratamiento acupuntural del dolor lumbociático produjo analgesia en todos los pacientes tratados con este método, que además de ser inocuo, resultó de muy bajo costo y arrojó una diferencia de $ 8 513 en comparación con la técnica tradicional (AU)
Subject(s)
Low Back Pain/therapy , Sciatica/therapy , Acupuncture Analgesia/nursing , Nerve Block/nursingABSTRACT
Es una reflexión que hace la autora sobre el aborto provocado, plantea que el aborto es estudiado desde hace muchos siglos, en diferentes épocas y culturas. Expone algunos factores por las que se realiza un aborto provocado. Plantea que solamente Cuba y Puerto Rico, en América Latina han logrado la despenalización del aborto.Hace referencia a distintos aspectos relacionados con el tema
